Prospective, Phase II , non-randomised interventional case series of the safety and efficacy of the use of intra-vitreal bevacizumab ("Avastin") in the treatment of macular oedema secondary to diabetic retinopathy and uveitis, and for choroidal neovascular membranes secondary to uveitis, with respect to visual acuity and central macular thickness
Phase of Trial: Phase II
Latest Information Update: 23 Jun 2016
At a glance
- Drugs Bevacizumab (Primary)
- Indications Choroidal neovascularisation; Diabetic macular oedema; Retinal oedema
- Focus Therapeutic Use
- 19 Oct 2009 New trial record.